Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLK Allakos	$0.33	$0.33	$0.22 ▼ $1.56	$29.74M	0.15	1.20 million shs	N/A
BPMC Blueprint Medicines	$128.27 +0.1%	$113.55	$73.04 ▼ $128.52	$8.29B	0.89	1.33 million shs	1.35 million shs
GLPG Galapagos	$28.84 +1.0%	$27.84	$22.36 ▼ $31.23	N/A	0.07	251,584 shs	147,602 shs
IONS Ionis Pharmaceuticals	$42.98 -1.4%	$35.24	$23.95 ▼ $52.34	$6.84B	0.23	1.60 million shs	1.34 million shs
TGTX TG Therapeutics	$37.20 +2.5%	$36.77	$16.65 ▼ $46.48	$5.83B	1.91	2.92 million shs	681,323 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLK Allakos	0.00%	0.00%	0.00%	+4.48%	-56.70%
BPMC Blueprint Medicines	0.00%	+0.12%	+0.29%	+57.04%	+17.65%
GLPG Galapagos	0.00%	+3.06%	+3.13%	+21.41%	+15.85%
IONS Ionis Pharmaceuticals	0.00%	+7.99%	+21.96%	+58.66%	-5.75%
TGTX TG Therapeutics	0.00%	+1.31%	-5.34%	-0.40%	+97.98%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLK Allakos	2.8718 of 5 stars	3.1	0.0	4.7	0.0	2.5	1.3
BPMC Blueprint Medicines	1.5514 of 5 stars	2.1	4.0	0.0	2.1	0.8	0.6
GLPG Galapagos	0.332 of 5 stars	0.8	3.0	0.0	1.5	0.0	0.6
IONS Ionis Pharmaceuticals	4.6752 of 5 stars	4.4	2.0	3.0	3.3	3.3	0.6
TGTX TG Therapeutics	3.2905 of 5 stars	1.4	1.0	3.5	2.7	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLK Allakos	2.25	Hold	$2.00	507.72% Upside
BPMC Blueprint Medicines	2.27	Hold	$128.06	-0.16% Downside
GLPG Galapagos	1.50	Reduce	$25.33	-12.14% Downside
IONS Ionis Pharmaceuticals	2.78	Moderate Buy	$58.25	35.53% Upside
TGTX TG Therapeutics	2.80	Moderate Buy	$40.80	9.68% Upside

Current Analyst Ratings Breakdown

Latest ALLK, BPMC, IONS, GLPG, and TGTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	IONS Ionis Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$51.00 ➝ $57.00
6/26/2025	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
6/17/2025	BPMC Blueprint Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$143.00 ➝ $129.00
6/12/2025	IONS Ionis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$45.00 ➝ $48.00
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$88.00 ➝ $129.00
6/4/2025	BPMC Blueprint Medicines	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold	$83.00 ➝ $129.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$132.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLK Allakos	N/A	N/A	N/A	N/A	$1.93 per share	N/A
BPMC Blueprint Medicines	$508.82M	16.28	N/A	N/A	$4.70 per share	27.29
GLPG Galapagos	$298.31M	N/A	$0.73 per share	39.71	$47.57 per share	N/A
IONS Ionis Pharmaceuticals	$705M	9.70	N/A	N/A	$3.73 per share	11.52
TGTX TG Therapeutics	$329M	17.95	$0.12 per share	306.10	$1.43 per share	26.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLK Allakos	-$185.70M	-$1.32	N/A	N/A	N/A	N/A	-140.87%	-86.22%	8/6/2025 (Estimated)
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	197.34	N/A	-27.70%	-64.60%	-17.22%	7/30/2025 (Estimated)
GLPG Galapagos	$80.16M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/23/2025 (Estimated)
IONS Ionis Pharmaceuticals	-$453.90M	-$2.99	N/A	N/A	N/A	-63.65%	-91.85%	-15.77%	7/30/2025 (Estimated)
TGTX TG Therapeutics	$23.38M	$0.24	155.00	37.20	N/A	10.13%	18.88%	7.05%	8/5/2025 (Estimated)

Latest ALLK, BPMC, IONS, GLPG, and TGTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/23/2025	Q2 2025	GLPG Galapagos	-$0.34	N/A	N/A	N/A	$80.13 million	N/A
5/7/2025	Q1 2025	TGTX TG Therapeutics	$0.19	$0.03	-$0.16	$0.03	$117.07 million	$120.86 million
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million
4/30/2025	Q1 2025	IONS Ionis Pharmaceuticals	-$1.07	-$0.93	+$0.14	-$0.93	$144.31 million	$132.00 million
4/23/2025	Q1 2025	GLPG Galapagos	-$0.23	-$2.47	-$2.24	-$2.45	$72.22 million	$97.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLK Allakos	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
GLPG Galapagos	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLK Allakos	N/A	6.08	6.08
BPMC Blueprint Medicines	1.01	2.80	2.75
GLPG Galapagos	N/A	7.95	7.86
IONS Ionis Pharmaceuticals	2.63	9.66	9.62
TGTX TG Therapeutics	1.03	4.02	3.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLK Allakos	84.64%
BPMC Blueprint Medicines	N/A
GLPG Galapagos	32.46%
IONS Ionis Pharmaceuticals	93.86%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
ALLK Allakos	16.12%
BPMC Blueprint Medicines	4.21%
GLPG Galapagos	2.91%
IONS Ionis Pharmaceuticals	2.71%
TGTX TG Therapeutics	10.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLK Allakos	190	90.38 million	74.94 million	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
GLPG Galapagos	1,310	N/A	N/A	Optionable
IONS Ionis Pharmaceuticals	1,069	159.16 million	154.85 million	Optionable
TGTX TG Therapeutics	290	158.76 million	141.86 million	Optionable

ALLK, BPMC, IONS, GLPG, and TGTX Headlines

Recent News About These Companies

Braun Stacey Associates Inc. Has $19.82 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

July 5 at 8:41 AM | marketbeat.com

TG Therapeutics, Inc. (TGTX) - Yahoo Finance

July 3 at 5:24 PM | finance.yahoo.com

Jim Cramer on TG Therapeutics: “You Should Buy the Stock”

July 2, 2025 | insidermonkey.com

Kymera Therapeutics Shows Market Leadership With Jump To 93 RS Rating

July 2, 2025 | msn.com

Cramer's Lightning Round: TG Therapeutics is a buy

June 30, 2025 | nbcnewyork.comN

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Illinois Municipal Retirement Fund

June 30, 2025 | marketbeat.com

TGTX - TG Therapeutics Inc Financials - Morningstar

June 28, 2025 | morningstar.comM

TG Therapeutics: Strong Execution Tempered By An Evolving Market

June 28, 2025 | seekingalpha.com

Spire Wealth Management Acquires 22,750 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

June 28, 2025 | marketbeat.com

TGTX - TG Therapeutics Inc Valuation - Morningstar

June 27, 2025 | morningstar.comM

Stocks With Rising Relative Strength: CRISPR Therapeutics

June 26, 2025 | msn.com

TGTX TG Therapeutics, Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

TG Therapeutics: Another Possible Avenue Of MS Growth With Azer-Cel

June 25, 2025 | seekingalpha.com

Assenagon Asset Management S.A. Cuts Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

June 20, 2025 | marketbeat.com

Insider Selling: Yann Echelard Unloads $369K Of TG Therapeutics Stock

June 17, 2025 | benzinga.com

Are Options Traders Betting on a Big Move in TG Therapeutics Stock?

June 17, 2025 | msn.com

Yann Echelard Sells 10,000 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) Stock

June 17, 2025 | insidertrades.com

Insider Selling: TG Therapeutics, Inc. (NASDAQ:TGTX) Director Sells 10,000 Shares of Stock

June 16, 2025 | marketbeat.com

Cantor Fitzgerald Estimates TG Therapeutics FY2026 Earnings

June 10, 2025 | marketbeat.com

GAMMA Investing LLC Purchases 176,573 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

June 9, 2025 | marketbeat.com

TG Therapeutics (NasdaqCM:TGTX) Stock Rises 13% In Last Month

June 7, 2025 | uk.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!
By Thomas Hughes | June 16, 2025
View AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!
Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst
By Thomas Hughes | June 26, 2025
View Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst
2 Under the Radar Space & Defense Stocks With Huge Potential
By Leo Miller | July 1, 2025
View 2 Under the Radar Space & Defense Stocks With Huge Potential
As Oil Prices Rebound, These Stocks Could Fuel the Next Rally
By Sarah Horvath | June 9, 2025
View As Oil Prices Rebound, These Stocks Could Fuel the Next Rally

ALLK, BPMC, IONS, GLPG, and TGTX Company Descriptions

Allakos NASDAQ:ALLK

$0.33 0.00 (0.00%)

As of 05/15/2025

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Blueprint Medicines NASDAQ:BPMC

$128.27 +0.07 (+0.05%)

Closing price 07/3/2025 02:27 PM Eastern

Extended Trading

$128.27 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Galapagos NASDAQ:GLPG

$28.84 +0.29 (+1.00%)

As of 07/3/2025 01:04 PM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Ionis Pharmaceuticals NASDAQ:IONS

$42.98 -0.61 (-1.40%)

Closing price 07/3/2025 02:44 PM Eastern

Extended Trading

$42.64 -0.34 (-0.79%)

As of 07/3/2025 04:08 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

TG Therapeutics NASDAQ:TGTX

$37.20 +0.91 (+2.51%)

Closing price 07/3/2025 03:25 PM Eastern

Extended Trading

$36.94 -0.26 (-0.69%)

As of 07/3/2025 04:42 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time